User:Mr. Ibrahem/Trastuzumab deruxtecan

Trastuzumab deruxtecan, sold under the brand name Enhertu, is a medication used to treat breast cancer and gastric or gastroesophageal adenocarcinoma. Specifically it is used for HER2 positive disease. It is given by gradual injection into a vein.

Common side effects include nausea, tiredness, hair loss, constipation, low red blood cells, low white blood cells, low platelets, and headache. Other side effects may include low potassium, arrhythmias, interstitial lung disease, and liver problems. Use in pregnancy may harm the baby. It is the monoclonal antibody trastuzumab linked to the topoisomerase I inhibitor deruxtecan. Trastuzumab binds to epidermal growth factor receptor 2 (HER2/neu) while deruxtecan blocks a cell's ability to make DNA.

Trastuzumab deruxtecan was approved for medical use in the United States in 2019, Japan in 2020, Europe and Australia in 2021. In the United Kingdom it costs the NHS about £1,450 as of 2021 for 100 mg. This amount in the United States is about 2,500 USD.